Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth

Status: open

[921786-3] PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834

Description

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer. Assessment of a variety of correlative analysis, including evaluation of the effect of palbociclib in genomically defined tumor subgroups, is planned. IRB Number 16-208

Sponsors

This trial is sponsored by Alliance Foundation Trials, LLC.

Providers Associated With This Trial

Sub Investigators

This link will open in a new tab or window.